Large-scale immune monitoring experiments (such as clinical trials) are a promising direction for 16 biomarker discovery and responder stratification in immunotherapy. Mass cytometry is one of the 17 tools in the immune monitoring arsenal. We propose a standardized workflow for the acquisition and 18
Introduction 28
Immune monitoring (IM) is a systems biology approach for the quantitative evaluation of the state of 29 the immune system (Brodin and Davis, 2017, Kaczorowski et al., 2017) . Changes in hematopoietic 30 cell subset composition and in the cytokines and other proteins these cells produce can indicate the 31 nature and severity of the stress the body is confronting. These immune correlates establish 32 measurable proxies to the hidden details of disease or the effects of treatment, and are promising to 33 become a central component of clinical research (Kohrt et al., 2016 Any large-scale study will introduce challenges such as sample quality control, batch effects, and 43 inter-operator variability. There are a plethora of methods to address potential data quality issues in 44 mass cytometry. These include the incorporation of normalization beads into the sample (Finck et al., 45 2013), reduction of technical variability and doublets through multi-sample barcoding (Zunder et al., 46 2015, Fread et al., 2017) , measurement of batch effects using spiked-in references (Kleinsteuber et 47 al., 2016) , compensation of signal spillover across different masses (Chevrier et al., 2018) , and 48 others. However, despite the well-developed ecosystem, there is no clear standard on how to run a 49 large-scale mass cytometry study, and researchers are often forced to reinvent the wheel by designing 50 experiments de novo with no clear guidance on best practices. 51
The situation is even more problematic in the computational biology arena. Numerous mass 52 cytometry analysis methods have been published. These can be broadly classified into one of two 53 categories. Clustering algorithms, such as SPADE (Qiu et consuming, error prone, susceptible to operator bias, and not easily scalable. 63
Finally, the insights gained from mass cytometry ultimately depend on the antibodies used in a given 64 staining panel, and as with any other antibody-guided assay, antibody selection is a central 65 component of mass cytometry experiment design. While there is some consensus on appropriate 66 markers to identify major circulating immune subsets (Maecker et al., 2012) , much of the potential of 67 mass cytometry is in its ability to characterize the roles of less-studied markers (Horowitz et After staining, the samples were then divided into two aliquots, one of which was fixed with freshly 104 diluted 1.6% formaldehyde in PBS for 20 mins, while the other was left untreated. Each of the 6 105 samples was then barcoded using a combinatorial CD45-based barcoding scheme (Figure 1 ), 106 allowing the 6 treatments to be combined as a single sample. This pooled sample of ~300 million 107 cells was then evenly distributed across each of the 372 wells of a LEGENDScreen kit (BioLegend) 108 containing reconstituted PE antibodies (Supplementary Table 2) , and incubated for 30 minutes on 109 ice. Cells from each well were then washed and fixed with 1.6% formaldehyde in PBS for 20 mins. 110
To reduce the overall number of samples to facilitate subsequent processing and data acquisition, the 111 samples were washed with barcode permeabilization buffer (Fluidigm), and sets of 10 wells were 112 barcoded and pooled using a combinatorial palladium-based barcoding strategy ( Figure 1 The individual samples were then labeled using the Ek'balam algorithm (Supplementary Table 3 ). 137
Each cell subset was clustered using the profiling step in Astrolabe (see below). For the purpose of 138 the Ek'balam algorithm, gdTCR intensities were compensated by 1.9% of CD8 intensity due to 139 known signal spillover due to oxide formation from the 146Nd-CD8 channel being detected in the 140 162Dy gdTCR channel. Platform output was downloaded in the form of R Programming Language 141 RDS files (R Core Team, 2013) for manual follow-up analysis. Figures were generated using ggplot 142 (Wickham, 2016) . To evaluate the quality of the the debarcoding, clustering and annotation in 143
Astrolabe and to perform independent analyses, a subsets of samples were processed in parallel using 144 a Matlab based debarcoding algorithm (Fread et al., 2017 ) and uploaded to Cytobank for manual 145 gating of major immune subsets. 146
The Ek'Balam algorithm 147
Ek'Balam is a hierarchy-based algorithm for labeling cell subsets which combines the strength of a 148 knowledge-based gating strategy with unbiased clustering. It receives a user-defined subset hierarchy 149 which details gating rules such as "Cells which are CD3+ are T Cells". Subsets can branch through 150 additional rules, for example, "T Cells which are CD4+ are CD4+ T Cells". The hierarchy is 151 organized into levels which correspond to parallel steps when gating. For example, the first level 152
could include "CD3+ are T Cells", "CD19+ are B Cells", and "CD33+ 
Recall is the frequency of correctly classified target events out of all target events, or TP / (TP + FN). 179 180
The F1 score is the harmonic mean of precision and recall, or 181
The Matthews Correlation Coefficient (MCC) is the correlation coefficient between the 182 computational and manual classification, or 183
Average overlap frequency (AOF) 184
The average overlap frequency is a metric of staining and clustering quality of a given marker (Amir 185 et al., 2018). It assumes that the marker has two modalities, denoted negative and positive. The AOF 186 is a value between 0 and 1, where 0 is complete separation between the modalities and 1 is complete 187 overlap, and is defined as: 188
This is a provisional file, not the final typeset article distribution with a mean and standard deviation of , and 
Percent positive events 197
For each (profiling subset, antibody), the percent of positive events is the percent of events whose 198 intensity is greater than the 99th percentile of all events in the Blank LEGENDScreen well (well A1 199 in plate 1, see Supplementary Figure 3 ). This well does not include any PE-conjugated antibodies, so 200 the intensity distribution there is a background for anti-PE measurement using the Helios. 201
Results 202

Design of an Integrated Pipeline for the Acquisition and Analysis of Large Immune 203
Monitoring Experiments 204
Conducting a large-scale immune monitoring experiment over a long period of time using mass 205 cytometry raises several challenges. One, it is imperative to monitor instrument performance and 206 evaluate sample data quality to identify transient fluctuations in instrument performance resulting in 207 features such as diminished staining for one or more markers, higher than usual debris or doublet 208 count. Two, batch effects due to experimental or instrument variation can be a significant concern. 209 While researchers should always be aware of how technical sources could lead to variation, this is 210 especially pertinent when data is gathered and acquired over weeks or months. Experiment design 211 should therefore include mechanisms that detect both types of failures and alert the researcher 212 appropriately. Finally, the role of human operators should be minimized in order to reduce human-213 introduced variability. Decision making should follow a clear protocol or be entrusted to 214 computational methods. 215
The antibody expression data set described in this study integrates multiple techniques to minimize 216 experimental and technical reproducibility and streamline data acquisition and analysis ( Figure 1 ). 217
Peripheral blood mononuclear cell (PBMC) samples from three healthy donors ( Figure 1A ) were 218 stained with a 21-marker antibody panel comprised of markers to unambiguously identify all the 219 major immune compartments: B Cells, myeloid cells, NK Cells, and T Cells, together with further 220 granularity for subsets within these compartments (such as CD16+/-monocytes or naive versus 221 transitional B Cells). This core antibody panel was lyophilized as a single cocktail and the same 222 batch was used throughout sample acquisition to minimize experimental variability due to reagent 223 variability or pipetting. The panel only utilizes a subset of the channels available in mass cytometry, 224 allowing researchers to incorporate an additional 10-15 markers to address experiment-specific 225 questions. 226
Following initial core antibody panel staining, the samples were split into two groups to evaluate the 227 impact of fixation on each of the antibody epitopes subsequently evaluated in this screen. This design 228 also typifies a common experimental design where a treatment (fixation) is compared to control 229 (fresh samples). The six patient x treatment combinations were barcoded and pooled using a live cell-230 compatible doublet-free barcoding strategy leveraging CD45 antibodies conjugated to 4 distinct 231 isotopes. This barcode approach streamlines sample processing and minimizes potential variability 232 due to acquiring different patients or treatments at different times. The isotopes used for barcoding 233
were specifically chosen to ensure that potential spillover due to isotopic impurities or oxide 234 formation from these barcoding channels would not influence any of the other antibody channels 235 being measured in this experiment. Next, the samples were evenly distributed across each of the 372 236 wells of a LEGENDScreen kit, each of which includes a PE-conjugated antibody against a distinct 237 epitope. Following this with a metal-conjugated anti-PE antibody enabled the measurement of a 238 comprehensive set of surface markers across all the cell subsets identified by the broad lyophilized 239 panel. Finally, to streamline data acquisition, sets of 10 wells were further barcoded and combined 240 using a combinatorial strategy leveraging five palladium channels. 241
The resulting 38 batched samples were then acquired using a Helios mass cytometer ( Figure 1B ). 242
Acquisition required around 400 hours of instrument time over five weeks of operation and resulted 243 in a total of 63 million events. Analyzing such a large amount of data manually would have been 244
time-consuming and risked operator-introduced variability. To avoid these two issues, we employed 245 the standardized Astrolabe Cytometry Platform to debarcode and clean the data, label cell subsets, 246 and conduct unsupervised clustering ( Figure 3C ). The Astrolabe analysis took 24 hours, and the 247 platform's "Analysis" export was employed in all follow-up analyses. 248
Debarcoded Sample Data is Robust and Consistent Across the Screen Samples 249
The antibody staining data set involves a high number of samples, complex experiment design, a 250 long acquisition period, and advanced computational analysis, any of which could potentially 251 introduce variability or other artifacts. Several tests inspect the various stages of the experiment 252 (Figure 2 ). First and foremost, accurate debarcoding is critical for all follow-up analyses. This step is 253 especially challenging due to the two-tiered barcoding scheme employed: CD45-based barcoding of 254 patient x treatment and palladium-based barcoding of each batch of 10 LEGENDScreen antibodies. 255
Astrolabe correctly identifies all 60 codes and their channel profile are distinct and follow the 256 expected design (Figure 2A ). In order to validate the computational debarcoding approach, the results 257 were compared to manually-debarcoded data for one of the batches. The two methods showed high 258 concordance according to four different statistical metrics ( Figure 2B ), supporting the use of the more 259 efficient computational approach to debarcode all 2,232 samples. 260
The starting point for the data set was blood from three healthy donors. After the fixed versus fresh 261 treatment and the introduction of the kit's antibodies, each of these individuals leads to several 262 hundred different samples. However, the individual donor immune profile across each set of samples 263 are expected to be identical and therefore the acquired data should be highly comparable. This is 264 reflected in the principal component analysis (PCA) map over the sample cell subset frequencies 265 ( Figure 2C ). The samples are distributed across three well-separated islands. Each island corresponds 266 to one individual, signifying that the immune profile is consistent throughout acquisition. 267
We further applied Average Overlap Frequency (AOF) as a metric to evaluate individual marker 268 staining quality across all sample batches (Amir et al., 2018). This QC step identified issues with 269 staining of multiple markers in three of the batches (Supplementary Figure 1A) . Further inspection ofThis is a provisional file, not the final typeset article the score highlighted several problematic markers (Supplementary Figure 1B) . Evaluation of the 271 single-cell data for one of these markers, CD27, revealed a time-dependent increase in background 272 staining resulting in reduced marker resolution over time, which we attribute to a Helios instrument 273 malfunction during acquisition (Supplementary Figure 1C) . However, restricting analysis to only the 274 events in the first quarter of acquisition window for these batches resulted in AOF values within the 275 range of other batches, allowing recovery of valid antibody screening data despite the technical issues 276 (Supplementary Figure 1D) . The rapid identification, isolation, and solution of these technical 277 artifacts was facilitated by a standardized quality control approach using the well-defined AOF 278 metric. 279
Except for the batch effects identified by the AOF QC, the data set was consistent across cell subsets 280 and marker intensities ( Figure 2D ). For four major cell subsets (from top to bottom: T Cells, B Cells, 281 NK Cells, and CD14+ Monocytes), we examined the frequency in each sample (top panel of each, 282 ordered by batch). Subset frequency has very small variation across all the samples of a given donor. 283
Additionally, the distribution of the canonical marker of each subset (CD3, CD19, CD56, and CD14, 284 respectively) is also consistent across the samples (bottom panel of each, one box for each batch). 285
The combination of the above quality control measures highlights the overall robustness of the 286 antibody staining data set. The overall staining data were cohesive for each donor, and for each cell 287 subset across donors, and specific acquisition issues were identified and addressed using automated 288 QC metrics. 289
The Astrolabe Platform Correctly Labels Cell Subsets and Provides Meaningful 290
Unsupervised Clustering 291
The Astrolabe platform automatically labeled canonical immune cell subsets ( Figure 3) . As with 292 debarcoding, it is imperative to verify that automated cell annotation methods correspond to 293 historical definitions by calculating the overlap with manual gating. The Matthews Correlation 294 Coefficient (MCC) between the two methods was greater than 0.8 for almost all of the cell subsets 295 ( Figure 3A ). Biaxial plots of canonical markers further reinforced the overlap (Supplemental Figure  296 2A-C). Four of the subsets had a score lower than 0.8, which indicated some discrepancy between 297 computational labeling and manual gating. In all four cases, the disagreement was due to subjective 298 thresholding of a specific marker (Supplementary Figure 2D) : these are cases where the exact marker 299 intensity threshold for a given subset is ambiguous, such as where to draw the line on CD24 to 300 distinguish Naive and Transitional B Cells. Importantly, the automated approach allowed consistent 301 thresholding across all samples in these ambiguous cases, avoiding potential human subjectivity and 302 variability in assigning gates across samples. 303
The marker intensity profiles for each of the subsets labeled by the platform largely follow the 304 consensus HIPC definitions ( Figure 3B , Maecker et al., 2012) . Astrolabe consistently identified 11 T 305
Cell subsets (including CD4+ and CD8+ T cells, and Naive, EMRA, EM and CM subsets within 306 each), 6 B Cell subsets, several myeloid subsets, NK Cell subsets, granulocytes, and NKT Cells. 307
Examining cell subset frequencies across the three donors highlighted clear variability in their 308 respective immune profiles ( Figure 3C ), which further reinforces the previous PCA results. 309
The discovery of novel cell subsets defined by previously unappreciated marker expression patterns 310 is one of the most exciting promises of high-complexity cytometry such as mass cytometry. While 311 cell subset labeling follows established trends, unsupervised clustering has the potential to unearth 312 previously unknown signals. Astrolabe includes a profiling step, where each defined cell subset is 313 clustered separately ( Figure 3D ). The number of clusters is decided via a heuristic which depends on 314 the number of cells in each subset and on marker heterogeneity. In the antibody staining data set, the 315 platform returns 71 profiling subsets, which are then labeled according to the marker or markers that 316 provide the greatest separation between them. Notably, several CD8+ T Cell subsets are broken down 317 based on CD161, suggesting MAIT-like T Cells (Ussher et al., 2014) . Naive B Cells are 318 differentiated based on IgD, while NK Cells are broken up according to CD8. Similar to the 319 canonical cell subsets, profiling subset frequencies vary between the three donors ( Figure 3E ), 320
hinting at a wider heterogeneity within the population. 321
The Antibody Staining Data Set Defines Expression Patterns of Hundreds of Surface 322
Markers across 71 Cell Subsets 323 With 350 measured antibodies over 71 profiling subsets, the antibody staining data set is a rich 324 source of information about expected expression patterns in a healthy immune system. In order to 325 provide an initial view into the full expression dataset, we calculated two metrics for each profiling 326 subset and antibody combination ( Figure 4A, Supplementary Figure 3) . The first metric is the median 327 marker intensity, which is most useful in defining expression of markers that show a unimodal 328 distribution within a given subset. To better reflect bimodal expression patterns, or those in which 329 only a subset of cells are positive for a given marker, we used a blank well that lacked any PE-330 primary antibody to establish a baseline for the second metric, percent positive cells. We set an 331 arbitrary cutoff at the 99th percentile of the blank well and defined any cell above this value as 332 positive for the marker. The resulting heat map provides two separate summary statistics of marker 333 expression over all profiling subsets. 334
Focusing on any specific section of the heat map reveals a plethora of relevant patterns. The top of 335 the map is populated with well-established markers ( Figure 4B ) such as CD7, which is present on all 336 T Cell and NK Cell profiles, and CD11b, which is most highly expressed by monocytes. This section 337 also highlights a limitation of the data set with CD5: while this is generally considered a pan-T cell 338 marker the screen only showed expression on Naive CD4+ T Cells, and not any other CD4+ T Cells. 339
This idiosyncratic staining pattern could be due to many potential reasons, such as limitations of the 340 LEGENDScreen kit, antibody clone used, or specifics of the Helios protocol that we employed. This 341 serves as an important reminder to researchers who are looking to utilize this resource: as with any 342 other biological screen, specific signals should be further validated before being relied upon. 343
Lower sections of the heat map allow investigation of many surface markers that appear less 344 frequently in the scientific literature ( Figure 4C) . Notably, the screen reproduces the expression of 345 CD180 in B Cells (Miura et al., 1998) whether there is a high degree of myeloid cell heterogeneity that still remains to be defined. This 350 trend continues throughout the heat map ( Figure 4D ), as are some more elusive signals, such as 351 CD371, which has a checkered expression pattern across diverse and seemingly unrelated profiling 352 subsets. 353
In order to provide some outside validation for the dataset, we conducted a second independent 354
LEGENDScreen experiment using PBMCs from a fourth donor and compared marker medians 355 ( Figure 4E ) and percent positive ( Figure 4F ) between the two experiments (Supplementary Memory (EM) CD8+ T Cells ( Figure 3D ). These profiling subsets were further explored for 375 differential marker expression trends ( Figure 5 ). Comparing the percent positive metric for each 376 antibody and looking for a consensus across all three donors identified six differentially expressed 377 markers in CM cells ( Figure 5A ) and four markers in EM cells ( Figure 5B ). 378
Two of these trends overlap between the two cell subsets: an increase in CD26 and a decrease in 379
CD49d. CD26 has been previously associated with MAIT cells (Dusseaux et al., 2011) . When 380 examining anti-PE in the CD26 LEGENDScreen well ( Figure 5C ), there is a x4.5 fold increase in 381 intensity on average between CD161-and CD161+ CM cells and a x7.2 fold increase on average 382 between CD161-and CD161+ EM cells. For CD49d, the average decrease in intensity is x1.2 and 383 x1.5, respectively, which is to be expected given the overall low intensity for that marker. 384 CD192 (CCR2) was differentially expressed between CD161hi and CD161low CM cells, with a x3.6 385 average fold increase in intensity in the CD161hi subset ( Figure 5D , left). It was only differentially 386 expressed for two of the three donors in EM cells ( figure 5D, right) . CD192 is involved in 387 recruitment of monocytes to inflammatory sites (Tsou et al., 2007) , a function that could potentially 388 be shared by MAIT cells. When examining marker intensities on a single-cell level, the CD161hi 389 cells are situated between the CD161low cells and monocytes, and would thus be classified as 390
CD192mid using standard gating nomenclature. In addition to these markers that were selectively 391 upregulated on CD161hi cells, the screen highlighted reduced expression of CD183 on CD161hi CM 392 cells ( Figure 5E ) and CD57 on CD161hi EM cells ( Figure 5F ). 393
One of the limitations of this screening approach is that each of the antibodies is profiled 394 independently, which precludes co-expression analyses of markers in the screen. To validate and 395 further explore the co-expression patterns of the markers identified in the screen, we independently 396 stained a healthy donor PBMC sample with a panel incorporating several of the differentially 397 expressed markers identified in the screen together with Va7.2 TCR to definitively identify MAIT 398 cells (Supplementary Table 5 ). tSNE analysis on the gated CD8 T cells revealed that the CD161hi 399 population had a distinct phenotype in high dimensional space defined by co-expression of many of 400 the markers identified in the screen ( Figure 5G and Supplementary Figure 5) . The differential 401 expression patterns of CD26, CD192, CD183, and CD57 between the CD161hi and CD161low 402 largely mirrored those see in the initial screen, independently validating these results ( Figure 5H) . 403 Figure 6 ). However, given the prevalence and importance of 407 fixation in cytometry experiments, there is an urgent need for a systematic study of the effect of 408 fixation on marker intensity to better inform marker selection and panel design in studies involving 409 fixed samples. 410
Sample Fixation Leads to Both Loss and Gain in the Intensity of Specific Markers
The antibody staining data set includes two conditions for each donor and antibody samples: one 411 stained fresh and stained following fixation with 1.6% formaldehyde. 255 of the LEGENDScreen 412 markers have cells whose intensity is higher than the blank threshold. For each of these markers, we 413 calculated the ratio between median expression in each of the conditions over all cell subsets (Figure  414 6A). We arbitrarily set a threshold of two-fold change as indicative of a significant intensity shift 415 between the conditions. 173 (68%) of the markers were below that threshold suggesting that they are 416 not notably affected by fixation. 417
Sixty-five of the markers have a two-fold or more increase in fixed samples relative to fresh ( Figure  418 6B). In other words, these markers gained additional signal when the sample was fixed. This increase 419 in expression can either be an artifact of fixation or true expression of an antigen that was not 420 detected in the corresponding fresh sample. While formaldehyde fixation may be expected to 421 partially comprise the cell membrane, the samples in this screen were not explicitly treated with any 422 permeabilizing agents, so we do not anticipate significant exposure of intracellular antigens. 423
Furthermore, gains in expression were largely seen across most cell subsets, suggesting that in most 424 cases these reflect non-specific staining artifacts following fixation. At the opposite end of the 425 spectrum, 17 markers showed a two-fold or more decrease from fresh to fixed and were thus 426 classified as loss of signal ( Figure 6C ). Since only an existing signal can diminish, the lost pattern is 427 specific to certain subsets. 428
Examining the ratio between the medians enables a broad survey of all antibodies over all subsets. 429 However, it ignores the single-cell nature of the data. Closer examination of several marker intensity 430 distributions reveals that when the median is around zero, the underlying distribution is usually 431 maintained from fresh to fixed as well ( Figure 6D ). When marker intensity is gained, it typically only 432 affects some of the cells within the subsets, while the low expression persists in others ( Figure 6E ). 433
On the other hand, when signal is lost, it appears that fixation diminishes it completely ( Figure 6F ). 434
These trends further reinforce the hypothesis that the signal gained by fixation is due to the protocol 435 rather than the underlying biology. In almost all cases, changes in markers expression patterns 436 showed similar trends across subsets expressing that marker. One notable expression was CD22, 437 which was found to be expressed on both B cells and basophils in the fresh samples using the clone 438 contained in the Legendscreen panel (S-HCL-1), consistent with previous descriptions of clone-439 specific CD22 expression on basophils (Han et al., 1999 , Han et al., 2000 . However, fixation 440 resulted in loss of expression specifically on basophils, but not on B cells (Figure 6G ), reflecting 441 differences in the fixation sensitivity of the CD22 conformational epitopes that are differentially 442 expressed between B cells and basophils (Toba et al., 2002) . 443
The LEGENDScreen kit includes antibodies conjugated to PE which are then measured by mass 444 cytometry using an anti-PE secondary. It is possible that the effects of fixation observed here are notThis is a provisional file, not the final typeset article due to effects on the underlying antibody, but rather due to a more complex interaction that 446 potentially includes the marker antibody, PE, and anti-PE. We therefore performed a validation 447 experiment where seven of the gain or loss markers were incorporated into the mass cytometry panel 448
( Figure 6H ). For the three loss markers, the validation results confirm the effect we saw in the data 449 set: the same subsets express these markers, and loss their signal after fixation. On the other hand, the 450 results for the gain markers were mixed. While one of them (CXCR3) fully reproduced the screen 451 results, the other two only lost their signal in some of the cell subsets. 452
Cytometry experiment design can be a daunting task due to the high number of variables that needs 453 to be considered. There are many factors that could influence results in unknown ways, especially 454 when employing a method such as fixation that has the potential to perturb the chemistry and kinetics 455 underlying the assay. This antibody staining data set represents an accessible resource to identify and 456 anticipate such potential effects. 457
Discusion 458
We present a standardized workflow for the acquisition and analysis of large-scale immune 459 monitoring studies using mass cytometry. The workflow incorporates several established 460 experimental techniques in order to reduce signal variation within samples, across samples, and 461 across operators. One, it utilizes a lyophilized core antibody panel that allows clear identification of 462 major compartments of the immune system and provides higher resolution into T Cell, B Cell, and 463 other subsets. Lyophilization streamlines sample processing and eliminates the variability inherent in 464 pipetting small volumes from a large numbers of individual antibody vials. Two, a two-tiered 465 barcoding scheme assures that all donors and treatments are acquired together and that samples are 466 organized into batches. This reduces the technical variation associated with the instrument and its 467 operation. Three, a fully automated cloud-based analytics platform (Astrolabe) runs the same quality 468 control, data cleaning, cell subset labeling, and unsupervised clustering over the entire data set. 469
Taken together, the workflow provides a flexible framework that can be easily adapted to clinical 470 trial immune monitoring or other large-scale experiments and greatly improve the quality, 471 reproducibility, robustness and utility of mass cytometry data. 472
We leveraged this standardized workflow as part of a comprehensive screen to establish the 473 expression of 350 surface markers across all major circulating immune subsets at single cell 474 resolution. Acquisition of the entire expression dataset across three donors required more than a 475 month of Helios operation and culminated in over 60 million events; one of the largest single mass 476 cytometry datasets recorded to date. 477
Several quality control approaches were included in order to ensure the accuracy and quality of the 478 antibody staining dataset. First, we employed a two-tier barcoding approach to minimize technical 479 variability in performing the screen. The barcoded samples were deconvolved using an automated 480 debarcoding approach that was directly compared and shown to perform comparably to manual 481 debarcoding. Second, we used average overlap frequency (AOF) as a metric to evaluate the 482 consistency of individual marker staining quality across all samples, which allows us to identify and 483 address acquisition batch effects. Third, we used an automated approach to identify and label cell 484 subsets, the accuracy of which was validated against manual gating of each of the analogous subsets, 485 demonstrating high overlap and consistency between these approaches. Fifth, we performed the 486 screen using three independent donor blood samples to allow for an evaluation of the biological 487 reproducibility of individual marker expression profiles, and each donor presented a consistent and 488 distinct cell subset profile across the entire experiment with both the frequencies of the major 489 immune compartments and the intensities of their canonical markers showing low variability across 490 the entire acquisition period. Finally, the reproducibility of the antibody expression profiles in our 491 primary screen were further validated using a second independent screen performed using an 492 additional donor. Taken together, these steps highlight the fidelity of the antibody staining resource. 493
However, it is still important to note the limitations of this data set as a high-throughput screen; any 494 findings require independent follow-up to confirm whether the reported expression patterns truly 495 reflect hitherto unknown phenotypic diversity or may reflect specific biological or technical aspects 496 of this screen. As an illustration of this approach, we used the screen to identify potential markers to 497 characterize CD161+ MAIT cells, and then performed an independent experiment where we 498 incorporated these markers as part of a single CyTOF panel. This allowed us to both independently 499 validated the markers identified the screen and to further explore their co-expression patterns, 500
confirming that CD161hi MAIT cells can be further characterized as being CD26hi, CD192hi, 501
CD183low and CD57low. 502
In addition to screening marker expression patterns on fresh cells, we also introduced formaldehyde 503 fixation as a treatment, thoroughly examining the influence that this standard perturbation could have 504 on surface marker staining. When examining the effect of fixation on marker expression patterns, 173 505 out of 255 expressed markers had no change in their intensity. 65 gained some signal from fresh to 506 fixed. We hypothesize that this gain is an artifact of the fixation protocol rather than a novel 507 biological signal since it was subset agnostic and only affected some of the cells in each profiling 508 subset. 17 markers lost their existing signal after fixation. In almost all cases, the loss of signal 509 affected all expressing subsets. The one exception was CD22, where one expressing subset 510 (basophils) lost the signal, while another (B Cells) did not. It has previously been suggested that the 511 CD22 epitope on basophils is conformationally distinct from that on B cells (Toba et al., 2002) . Our 512 data provide further evidence suggesting a difference in the fixation sensitivity of the CD22 epitopes 513 expressed on these two cell types. 514
The overall antibody staining data set is a powerful asset for immunologists seeking to investigate the 515 immune system through the lens of less-explored markers and develop antibody panels to focus on 516 specific cell subsets. To maximize the utility of this versatile qualitative resource, these results are 517 fully accessible through an interactive website at 518 https://www.astrolabediagnostics.com/antibody_staining_data_set. We included two aggregate 519 statistics for each (marker, subset) combination: median anti-PE intensity and percent positive cells 520 (which was calculated based on the background intensity available in the Blank LEGENDScreen 521 well). In addition to interacting with the dataset through heat maps, survey aggregate statistics for 522 their marker(s) and cell subset(s) of choice, the website allows investigators to delve deeper into the 523 single-cell resolution and the relevant distributions. Overall, this dataset represents an accessible and 524 unbiased resource for assessing potential expression of various markers over a large range of immune 525 subsets in healthy individuals and surveying the statistics in the entire data set reveals intriguing 526 signals for potential expression of less-studied markers. This study offers a valuable new resource to 527 aid in the design of high dimensional antibody panels for immune monitoring studies, and further 528 offers a template for a robust experimental workflow incorporating several components to ensure the 529 accuracy and robustness of data generated using mass cytometry technology. 530
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